

ASMS 2017 ThP090

Davide Vecchietti<sup>1</sup>, Claudio Ghilardi<sup>1</sup>, Katharina Kern<sup>2</sup>, Stephane Moreau<sup>3</sup>, Isabel Cabruja<sup>1</sup> 1 Shimadzu Italia, Milano, Italy, 2 RECIPE Chemicals + Instruments GmbH, Munich, Germany, 3 Shimadzu Europe GmbH, Duisburg, Germany



## Introduction

Tricyclic antidepressants (TCAs) are a group of psychoactive drugs which are mainly used for the therapy of endogene depressions, anxiety and pain management. The therapeutic drug monitoring of these molecules needs to be accomplished by extremely accurate techniques due to the narrow therapeutic range and to the severe adverse effect caused by overdosing. Liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS) shows

high sensitivity and specificity. Nevertheless, LC-MS/MS approaches mostly lack standardization and the necessary throughput for the application in routine analysis. We report a fully automated platform for the quantitation of more than 13 TCAs in serum samples with high throughput and no need for manual sample preparation (the present work is intended for Research use only).

Figure 1: Some of the most common Tryciclic Antidepressants.

## Methods and Materials

The analysis of TCAs was performed using a fully automatic LCMS preparation Unit (CLAM-2000, Shimadzu, for research use only) online with HPLC-LCMS (NexeraX2-LCMS8060, Shimadzu) starting from serum samples using the "ClinMass® TDM Kit System" (Recipe, MS9100). Samples (Reference material: human serum samples), calibrators and Internal standard mix (Recipe,

ClinMass® MS9112) were loaded onto the CLAM-2000 (refrigerated at 8°C). The treated samples were separated by the analytical column (Recipe, MS9030) at 40°C with a binary gradient system at a flow rate of 0.6 ml/min in 3.8 min (Table 1). Quantification was performed using optimized MRM transitions and Internal standard calibration methods.



Table 1: Analytical conditions and source parameters.

[LC] NexeraX2 System	
Column Temp.	: 40°C
Time Program	: gradient A-B 3.8 min
Injection Volume	: 0.5 µL
[MS] LCMS-8060	
Ionization	: ESI Positive
Nebulizer Gas	: 3 L/min
Interface temperature	: 300°C
Desolvation Line	: 250°C
Heat Block temperature	: 400°C
Drying Gas	: 10 L/min
Scan Type	: MRM

### Analytical conditions

The TCAs were quantified using MRM transitions listed in Table 2.

Table 2: MRM transitions for TCAs

Name	Quantifier ions	Qualifier ions	Name	Quantifier ions	Qualifier ions	
d8-Norclozapine	321.20>192.10		d3-Imipramine	284.20>61.20		
Norclozapine	313.10>192.10	313.10>269.90	Nortimipramine	281.20>44.20	281.20>55.20	
d3-Nordoxepin	269.20>107.10		Imipramine	281.20>58.20	281.20>86.20	
Nordoxepin	266.20>107.10	266.20>44.20	d4-Clozapine	331.10>191.90		
d3-Doxepin	283.20>107.10		Clozapine	327.00>192.00	327.00>270.00	
Doxepin	280.10>107.10	280.10>58.30	d3-Amitriptyline	281.20>105.10		
Desipramine	267.20>72.00	267.20>44.20	Norclomipramine	301.10>72.20	301.10>44.20	
d3-Desipramine	270.20>75.20		Amitriptyline	278.10>105.10	278.10>233.00	
Normaprotiline	264.20>169.20	264.20>219.10	d3-Norclomipramine	304.00>75.20		
Protriptyline	264.20>233.10	264.20>155.10	d3-Trimipramine	298.20>103.00		
d3-Nortriptyline	267.20>91.20		Trimipramine	295.20>100.20	295.20>58.20	
Nortriptyline	264.20>233.10	264.20>91.10	d3-Clomipramine	318.20>89.20		
Maprotiline	278.20>250.20	278.20>178.10	Clomipramine	315.20>86.20	315.20>58.20	
d5-Maprotiline	283.20>255.20					



The CLAM-2000 was programmed to perform sample extraction and protein precipitation followed by filtration and sample collection (Figure 2).



Figure 2: CLAM-2000 online with Nexera X2 system and LCMS-8060 triple quadrupole mass spectrometer.

## Results

#### Fully Automated sample preparation

Prior to the LC-MS/MS analysis a sample preparation is carried out in order to remove the sample matrix and to spike the sample with an internal standard.

Using the ClinMass® MS9100 kit (Recipe) it is possible to perform both extraction and IS spike with a single step, nevertheless with this procedure many manual steps are required in order to complete the sample preparation. This procedure is time consuming and could be affected by bias caused by the operator due to the liquid transfer steps that are required (Figure 3), moreover it is difficult to maintain the traceability of each steps for all the processed samples.

Using the CLAM-2000 it was possible to obtain a complete integration of sample preparation steps with

the LC-MS/MS quantification.

The samples were loaded onto the CLAM-2000 using microvials and/or primary sample collection vials. The fully automatic preparation/analysis procedure was performed as follows: I) 60 ul of IS std mix were dispensed in a filtration-collection vial (reagent for protein precipitation); II) 30 ul of serum sample were added;; III) stirring and incubation (1 min); IV) filtration for 0.45 min (deproteinization); the sample was finally transported to the LCMS system without human intervention (Figure 3). After LC-MS/MS analysis a data report was directly visualized by the CLAM-2000 control software.






Figure 3: CLAM-2000 fully automated sample preparation and analysis.

Due to the overlapped sample preparation the throughput of the instrument was

1 result each 5 minutes for quantification of all TCAs.

#### Linearity, Accuracy and Precision

The linearity and accuracy of the method was evaluated using 3 reference serum calibrators levels (Recipe MS9213). For all the analytes linearity and accuracy were within the analytical acceptable range (85%-115%). Furthermore in order to estimate the precision of the method, reference serum samples (Recipe MS9182)

spanning from low concentration level (Figure 4) to high concentration level were analyzed several times (6 replicates). For all analytes the CV% values were within acceptable analytical ranges. The same experiment was repeated for 3 non-consecutive days in order to estimate the inter-day precision (Table 3).



Table 3: Linearity, Accuracy, and precision evaluated using ClinChek ® MS9182 reference serum controls. \*n=6 replicates; \*\*n=3 non-consecutive days.

	R <sup>2</sup>	A CCI	PRECISION (%CV)				BIAS %				
		R <sup>2</sup> ACCURA		INTRA	DAY*	INTERDAY**		INTRADAY*		INTERDAY**	
		min	max	Low	High	Low	High	Low	High	Low	High
Amitriptyline	0.999	98.2	100	2.82	2.22	2.99	2.19	2.97	0.75	6.71	5.32
Clomipramine	0.999	99.3	100	1.80	1.09	2.94	1.46	0.82	2.93	1.86	3.23
Clozapine	0.999	96.9	101	2.45	2.17	2.70	2.71	2.71	4.96	2.13	5.42
Desipramine	0.999	96.9	104	2.07	2.80	2.65	2.49	2.17	0.90	2.60	2.06
Doxepin	0.999	88.8	102	4.29	2.21	2.39	1.70	3.87	1.50	5.56	3.37
Imipramine	0.999	96.1	105	2.47	1.88	2.59	2.40	0.83	0.11	2.95	1.95
Maprotiline	0.999	93.5	101	0.98	3.75	1.60	1.99	4.63	5.42	3.51	3.17
Norclomipramine	0.999	97.9	103	5.10	3.16	3.74	2.68	2.75	6.66	3.36	2.94
Norclozapine	0.999	95.8	101	2.96	3.12	2.68	2.41	7.58	3.86	4.19	4.04
Nordoxepin	0.999	91.4	102	2.47	2.74	2.06	2.18	1.64	0.65	1.76	2.22
Nortimipramine	0.999	97.4	104	3.69	3.45	5.59	5.13	3.03	1.77	8.21	3.31
Nortriptyline	0.999	92.8	110	7.84	5.50	6.42	5.49	5.85	4.88	5.77	6.46
Protriptyline	0.999	94.6	101	2.47	3.01	3.73	3.87	8.15	1.17	4.53	1.54
Trimipramine	0.999	97.6	103	2.91	3.47	2.89	2.65	13.60	10.46	11.30	6.89
Normaprotiline	0.999	96.5	105	4.51	4.71	7.87	4.97	8.22	10.37	7.01	12.79




Figure 4: Chromatograms of TCAs at LLOQ.



## Conclusions

- Fully Automated sample preparation procedure resulted suitable for the quantitation of Tricyclic Antidepressant by elimination of all manual preparation steps.
- The automation of the method increases the analytical performance, reduces the risk for human operators and due to the reduced reagent consumption, reduces also the cost of the analysis.

Disclaimer: The products and applications in this presentation are intended for Research Use Only (RUO). Not for use in diagnostic procedures. Not available in the USA, Canada and China.



Shimadzu Corporation www.shimadzu.com/an/

#### For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®".

Third-party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

First Edition: June, 2017